{
  "market_insights": {
    "segment": "Metabolic oncology",
    "gap_score": 8.2,
    "rationale": "High unmet need for metabolic modulators in oncology; few approved indications and fragmented competition.",
    "estimated_addressable_market_usd_m": 450,
    "key_competitors": ["BigPharmA", "SmallBio LLC"],
    "payer_pressure": "Moderate",
    "recommended_strategy": "Pursue low-cost reformulation + biomarker-led trial to de-risk adoption."
  }
}
